Investigating the link between AMH levels and embryo ploidy status
Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst? A Prospective Study
This study is trying to see if the levels of a hormone called AMH in the ovaries can help predict the quality of embryos created during fertility treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | ART Fertility Clinics LLC Academic / other |
| Locations | 1 site (Abu Dhabi, Abu Dhabi Emirate) |
| Trial ID | NCT05837325 on ClinicalTrials.gov |
What this trial studies
This observational study aims to determine if there is a correlation between intrafollicular levels of Anti-Müllerian hormone (AMH) and the ploidy status of blastocysts on the day of egg retrieval after ovarian stimulation for intracytoplasmic sperm injection (ICSI). By analyzing hormonal environments surrounding oocytes and utilizing Next Generation Sequencing (NGS) to assess chromosomal pairs, the study seeks to provide insights into embryo quality and implantation potential. Data will be collected and analyzed to enhance embryo selection and optimize ovarian stimulation protocols for better fertility outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 to 40 with at least one follicle from each ovary and normal menstrual cycles.
Not a fit: Patients with known chromosomal abnormalities or severe male factor infertility may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve embryo selection processes and increase the chances of successful pregnancies for women undergoing fertility treatments.
How similar studies have performed: While the use of AMH as a marker in fertility has been explored, this specific correlation with blastocyst ploidy status is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least one follicle from each ovary at day of trigger * Age from 18 to 40 years old * Normal menstrual cycle of 25-35 days * Poor, normal and high response will be included * First follicle punctured from each ovary will be consider for inclusion: if the COC (Cumulus Oocyte Complex) is present in clear FF (Follicular fluid), the FF will be collected separately for further analysis and the oocyte included in the study Exclusion Criteria: * Very hematic follicular fluid * If the COC is not found in the follicular fluid * Azoospermia * Known chromosomal abnormalities * Severe OAT (Oligoasthenoteratozoospermia)
Where this trial is running
Abu Dhabi, Abu Dhabi Emirate
- ART Fertility Clinics LLC — Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates (Recruiting)
Study contacts
- Principal investigator: Laura Melado, PhD — ART Fertility Clinics LLC
- Study coordinator: Barbara Lawrenz, PhD
- Email: barbara.lawrenz@artfertilityclinics.com
- Phone: 0097126528000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.